irinotecan has been researched along with 1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dicker, DT; El-Deiry, WS; Hong, B; Kline, CL; Kopelovich, L; Prabhu, VV; van den Heuvel, AP; Warfel, NA; Zhang, S; Zhou, L | 1 |
1 other study(ies) available for irinotecan and 1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one
| Article | Year |
|---|---|
Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Drug Synergism; Gene Knockdown Techniques; Genes, p53; Humans; Irinotecan; Neoplasm Proteins; Nitrofurans; Nuclear Proteins; Piperazines; Proteolysis; Proto-Oncogene Mas; Recombinant Fusion Proteins; RNA, Small Interfering; Signal Transduction; Tumor Protein p73; Tumor Stem Cell Assay; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |